Development and validation of active and passive immunotherapy targeted at protein Tau in transgenic mouse models for Alzheimer's disease KU Leuven
Over 30 million patients are affected worldwide by Alzheimers disease (AD), the most frequent and prominent type of dementia. Paralleling the graying of our society, resulting from improved hygiene and advanced medical care, the prevalence of dementia and in particular AD is expectedto quadruple by 2050. The dependence of a dementing person on the care of others for almost all daily tasks, poses a high financial and emotional burden on spouses, ...